Bluetongue virus proteins derived from baculovirus expression vectors have been administered in different combinations to sheep, a vertebrate host susceptible to bluetongue virus, and the neutralizing antibody responses were measured. Vaccinated sheep were subsequently challenged, and the indices of clinical reaction were calculated. The results indicated that the outer capsid protein VP2 alone in doses of >50 ,ug per sheep elicited protection. A dose of ca. 50 ,ug of VP2 protected some but not all sheep. However, when used in combination with ca. 20 ,ug of the other outer capsid protein, VP5, 50-F,g quantities of VP2 not only protected all the vaccinated sheep but also elicited a higher neutralizing-antibody response. The addition of viral core proteins VP1, VP3, VP6, and VP7, the nonstructural proteins NS1, NS2, and NS3, and the outer capsid proteins VP2 and VP5 did not enhance this neutralizing-antibody response.
Protection against a viral disease can be accomplished by using a live attenuated virus vaccine, an inactivated virus, or virus subunits either derived (extracted) from infectious material or produced by genetic engineering involving specific gene expression in a vector. Such vectors may be based on bacterial, yeast, or other cellular systems into which the gene is introduced. Certain viruses can also be used as vectors for gene expression.
Bluetongue virus (BTV) is the prototype of the genus Orbivirus (of the family Reoviridae) and is the causative agent of bluetongue disease in domestic ruminants, such as sheep and cattle. For nearly a century BTV has been associated with disease and mortality in sheep and cattle. At least 24 different serotypes (BTV-1, -2, etc.) have been identified from different parts of the world (3, 27) . Modified live vaccines have been developed in South Africa and in the United States. In South Africa, sheep are presently vaccinated with three pentavalent live attenuated virus vaccines at 3-week intervals. In the United States, although five BTV serotypes have been identified (BTV-2, -10, -11, -13, and -17), a modified live vaccine is only available for The 10 segments of the double-stranded RNA genome of BTV are located in the core of the virus particle. This core contains two major (VP3 and VP7) and three minor protein species (VP1, VP4, and VP6) and is surrounded by an outer capsid consisting of two major proteins, VP2 and VP5 (9, 18, 32, 33) . It has been demonstrated both in vivo (using intertypic reassortment viruses) (14) and in vitro (by translation of each RNA segment) (19) that BTV RNA segment 2 codes for VP2. Using immunoprecipitation techniques, Huismans and Erasmus (10) have shown that VP2 is a major serotype-specific antigen. This has been confirmed by analyzing intertypic reassortant viruses (14) . Huismans and associates (11) demonstrated that VP2 polypeptide recovered from purified BTV induced neutralizing antibodies and protected sheep against virulent viral challenge, indicating the potential of using VP2 as a subunit vaccine.
Conventional live attenuated vaccines have certain inherent deficiencies. In the case of BTV, such vaccines may cause fetal infection with resultant teratological defects.
When polyvalent vaccines are used, interference between component serotypes may occur, resulting in the development of incomplete immunity. Furthermore, since live attenuated vaccine strains are neutralized more readily by passive colostral immunity, they are less immunogenic in lambs than inactivated or subunit vaccines.
Genetic engineering techniques offer the possibility of preparing subunit vaccines without the need to grow the pathogenic organism. We recently reported the construction of a recombinant Autographa californica nuclear polyhedrosis virus (AcNPV) that expresses the VP2 protein of BTV-10, and we demonstrated that antisera raised against infected insect cell lysates derived from this virus contained neutralizing antibodies to BTV (13) . In this paper, we present a dose-related evaluation of the protective properties of the recombinant VP2 in sheep, a natural host of BTV. Selected combinations of VP2 with other BTV-10 antigens have also been analyzed (VP1, VP3, VP5, VP6, VP7, NS1, NS2, and NS3) (4, 5, 12, 28, 30, 31 ; J. J. A. Marshall and P. Roy, Virus Res., in press; C. P. Thomas and P. Roy, submitted for publication). The results of these studies on the development of recombinant subunit vaccines for bluetongue disease are discussed.
MATERIALS AND METHODS Virus and cells. AcNPV and recombinant virus stocks were grown and assayed in confluent monolayers of Spodoptera frugiperda cells in modified Grace medium (TC 100) containing 10% fetal bovine serum by the procedures described by Brown and Faulkner (2). BTV-10 was grown and assayed in confluent monolayers of either BHK-21 or Vero cells in Eagle medium containing 10% fetal bovine serum. Purified virus particles were obtained by using the methods described by Mertens et al. (20) (VP3), which came from BTV-17 (7, 16, 17, 23-26, 29, 35, 36) . The BTV genes were placed under the control of the AcNPV polyhedrin promoter as described previously (4, 5, 12, 13, 28, 30, 31; Marshall and Roy, in press). The recombinants were designated as follows: AcBTV-10.1 (VP1), AcBTV-10.2 (VP2), (VP3), AcBTV-10.5 (VP5), AcBTV-10.9 (VP6), (VP7), (NS1), AcBTV-10.8 (NS2), and AcBTV-10.10 (NS3). The BTV-10 VP4 gene was not available for the study.
To determine the concentration of BTV protein present in each extract of recombinant virus-infected cells, polypeptides were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis as described in Materials and Methods. The proteins were visualized by Coomassie blue staining (Fig. 1) (Fig. 2) . The 51-day serum of a sheep that received both the VP2 (50 ,ug) and VP5 (20 ,ug) precipitated both proteins, while VP2, VP3, VP5, and VP7 were detected in the immunoprecipitation analysis with the serum collected from a sheep that was immunized with a mixture of all nine BTV proteins (group V). None of the nonstructural proteins was immunoprecipitated by that serum. This was expected, since the nonstructural proteins are predominantly insoluble and should not have been present in the S100 fraction of the "S-labeled infected cells. VOL. 64, 1990 on August 14, 2017 by guest http://jvi.asm.org/
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In addition, the postchallenge blood of the control sheep was viremic, and their sera contained high plaque reduction titers, which is characteristic of a primary infection. DISCUSSION Baculovirus-expressed BTV proteins were used to induce neutralization antibodies in sheep and protection against virulent virus challenge. BTV-10 VP2 protein, in excess of 50 ,ug per sheep, elicited neutralizing antibodies and totally protected the animals. These results confirmed previous observations that the outer capsid protein VP2 is the main determinant of the neutralization-specific immune response (1, 10, 11, 13, 14) and that it induces protection (11) . Our data indicated that 50 ,ug of the expressed VP2 alone was insufficient to confer total protection. Two successive injections of 100 ,ug of VP2 provided full protection, a finding that closely correlates with that of Huismans and associates (11) . However, 50 ,ug of VP2 together with 20 ,ug of VP5 protected the sheep. Other amounts of the two antigens have yet to be assessed. Why the VP5 antigen enhances the neutralization (and protective) response is not known. No neutralizing monoclonal or monospecific antibody which reacts specifically with VP5 protein has yet been obtained. Recently, Mertens and associates (21) reported that both VP2 and VP5 are involved in the determination of BTV serotype response as analyzed by serum neutralization analyses of a reassortant virus. Our studies confirm that a combination of VP2 and VP5 antigens elicited significantly higher titers of BTVneutralizing antibodies. It is possible that VP5 enhances the immune responses indirectly by interaction with VP2 and by affecting the conformation of VP2 and, consequently, its serological properties. In this context, though, it is noteworthy that the VP5 proteins of Kemorovo serogroup orbiviruses elicit neutralizing-antibody responses (22) . It remains to be determined whether any of the BTV core proteins or nonstructural proteins play a role in protection and in the cellular immune response to BTV.
We have yet to determine the minimal amount of VP2 and VP5 antigens needed for complete protection and the duration of the immunity conferred by these antigens. It is also essential to perform similar vaccination trials in cattle, since cattle are a major reservoir host of BTV. Another important aspect of vaccine development is the role of adjuvant. Our data demonstrated that the incomplete Freund adjuvant enhanced the neutralizing-antibody responses in sheep. Whether other, more acceptable adjuvants are effective remains to be determined.
Previous studies involving cDNA-RNA hybridization experiments as well as complete sequence analysis of cDNA clones of viral RNA species have demonstrated that both outer capsid proteins VP2 and VP5 are among the most variable proteins of different BTV serotypes. Depending on the serotype, they exhibit sequence relationships to other BTV serotypes (6, 8, 26, 34) . Data that indicate that the antigens of one BTV serotype elicit antibody responses that neutralize the infection by other BTV serotypes (13) have been obtained. The extent that the baculovirus-expressed antigens representing a BTV serotype or heterologous combinations of VP2 and VP5 elicit immune responses that protect sheep against heterologous virus challenges needs to be determined.
